J-113,397
Clinical data | |
---|---|
Other names | J-113,397 |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
J-113,397 is an opioid drug which was the first compound found to be a highly selective antagonist for the nociceptin receptor, also known as the ORL-1 receptor.[1][2] It is several hundred times selective for the ORL-1 receptor over other opioid receptors,[3][4] and its effects in animals include preventing the development of tolerance to morphine,[5] the prevention of hyperalgesia induced by intracerebroventricular administration of nociceptin (orphanin FQ),[6] as well as the stimulation of dopamine release in the striatum,[7] which increases the rewarding effects of cocaine,[8] but may have clinical application in the treatment of Parkinson's disease.[9][10][11]
Synthesis
Patents for treating arrhythmia:[12]
Condensation between 1-Benzyl-3-methoxycarbonyl-4-piperidone [57611-47-9] (1) and
See also
- JTC-801
- LY-2940094
- SB-612,111
- Trap-101 (unsaturated olefin not reduced).
References
- PMID 10602690.
- PMID 11425589.
- PMID 10650183.
- PMID 17976996.
- S2CID 15569763.
- PMID 10940356.
- PMID 15282268.
- PMID 18082848.
- PMID 17287504.
- PMID 18413287.
- S2CID 46116472.
- ^ Guo Zheng, et al. CN 111249279 & CN 111265663 (2020).
- .
- ^ Satoshi Ozaki, et al. WO 1998054168 (to MSD KK).
- ^ Hiroshi Kawamoto, et al. WO 2000031061 (to MSD KK).